Chinese GLP-1 / Ozempic Alternatives

The GLP-1 weight-loss drug market is projected to reach $150B globally by 2030. China's early patent expiration creates a window for domestic manufacturers to produce biosimilar and improved versions of semaglutide before Western generics hit the market.

Innovent Biologics (partnered with Eli Lilly) is developing mazdutide, a dual GLP-1/glucagon agonist that showed superior weight-loss results in Phase III trials published May 2025. Multiple other Chinese firms are developing their own GLP-1 variants. Biotech out-licensing deal value from China jumped from $35B (2023) to $46B (2024).

The tradeoff: China's pharmaceutical regulatory system is faster but less transparent than the FDA. Western markets may be slow to accept Chinese-manufactured biologics. But for the 1.4 billion people in China — and billions more in the Global South — affordable GLP-1 drugs could transform obesity treatment.